Viewing nowCombinationSebikan Tablet 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Sintax Pharmaceutical Co., Ltd.

MFDS item code 201907788 · Approved 2019.11.07 · Insurance code 623006330
Treatment of essential hypertension not controlled by monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension who do not achieve sufficient control with monotherapy using amlodipine or olmesartan medoxomil. This helps stabilize blood pressure, preventing cardiovascular complications and improving health.
Take 1 tablet once daily with water, with or without food. It is recommended that the medication be taken at the same time each day (e.g., in the morning), if possible. Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and this medication is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not take this medication under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this drug's active ingredients or similar substances, pregnant or nursing women, individuals with severe liver dysfunction, patients with severe aortic stenosis, biliary obstruction, renal dialysis patients, patients in shock, and certain diabetic patients should not use this medication. Patients with hypotension due to lack of fluids or salt may experience initial hypotension, so their condition should be closely monitored, and appropriate measures should be taken if hypotension occurs. Also, sudden vasodilation can lead to hypotension, so special caution is required for patients with aortic stenosis. Patients with severe obstructive coronary artery disease should be cautious as the risk of angina or myocardial infarction may increase with this medication. Caution should be exercised in patients with heart failure, and patients with impaired renal function may experience changes in kidney function while taking this drug. In patients with liver dysfunction, metabolism of this drug may be slowed, necessitating dosage adjustments. While taking this medication, symptoms such as dizziness, headache, hypotension, edema, gastrointestinal symptoms may appear, so patients should consult their doctor if any unusual symptoms occur. This medication should be avoided during pregnancy due to risks to the fetus, and if breastfeeding, mothers should discontinue either breastfeeding or taking this medication as adverse reactions may occur in infants. It is not recommended for children under 18 years as safety and efficacy have not been established. Elderly patients may be more sensitive to this drug, so treatment should start at a low dose with dosage adjusted considering kidney and liver function. In cases of overdose, hypotension and decreased cardiac function may occur, necessitating immediate medical attention and continuous monitoring of blood pressure and cardiac status. This medication should be stored in a cool, dry place, avoiding moisture and heat, and kept out of reach of children; transferring to other containers should be avoided. Before starting this medication, patients must consult with a doctor or pharmacist regarding potential interactions with other medications they are currently taking.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Maintaining the storage temperature between 1 degree and 30 degrees Celsius is important. Doing so will help preserve the medication's effectiveness and prevent deterioration.
White round film-coated tablets
28 tablets/PTP [(14 tablets/PTP x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Sintax Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.